Cohn SL, Pearson AD, London WB et al (2009) The international neuroblastoma risk group (INRG) classification system: an INRG task force report. J Clin Oncol 27:289–297

Article  PubMed  PubMed Central  Google Scholar 

Bagatell R, McHugh K, Naranjo A et al (2016) Assessment of primary site response in children with high-risk neuroblastoma: an international multicenter study. J Clin Oncol 34:740–746

Article  PubMed  PubMed Central  Google Scholar 

Kreissman SG, Seeger RC, Matthay KK et al (2013) Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol 14:999–1008

Article  CAS  PubMed  PubMed Central  Google Scholar 

Matthay KK, Reynolds CP, Seeger RC et al (2009) Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children’s oncology group study. J Clin Oncol 27:1007–1013

Article  CAS  PubMed  PubMed Central  Google Scholar 

Park JR, Kreissman SG, London WB et al (2019) Effect of tandem autologous stem cell transplant vs single transplant on event-free survival in patients with high-risk neuroblastoma: a randomized clinical trial. JAMA 322:746–755

Article  PubMed  PubMed Central  Google Scholar 

Park JR, Bagatell R, Cohn SL et al (2017) Revisions to the international neuroblastoma response criteria: a consensus statement from the national cancer institute clinical trials planning meeting. J Clin Oncol 35:2580–2587

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bar-Sever Z, Biassoni L, Shulkin B et al (2018) Guidelines on nuclear medicine imaging in neuroblastoma. Eur J Nucl Med Mol Imaging 45:2009–2024

Article  CAS  PubMed  Google Scholar 

Sharp SE, Trout AT, Weiss BD, Gelfand MJ (2016) MIBG in neuroblastoma diagnostic imaging and therapy. Radiographics 36:258–278

Article  PubMed  Google Scholar 

Matthay KK, Edeline V, Lumbroso J et al (2003) Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol 21:2486–2491

Article  PubMed  Google Scholar 

Orr KE, McHugh K (2019) The new international neuroblastoma response criteria. Pediatr Radiol 49:1433–1440

Article  PubMed  Google Scholar 

Matthay KK, Shulkin B, Ladenstein R et al (2010) Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the international neuroblastoma risk group (INRG) task force. Br J Cancer 102:1319–1326

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee JW, Cho A, Yun M, Lee JD, Lyu CJ, Kang WJ (2015) Prognostic value of pretreatment FDG PET in pediatric neuroblastoma. Eur J Radiol 84:2633–2639

Article  PubMed  Google Scholar 

Li C, Zhang J, Chen S et al (2018) Prognostic value of metabolic indices and bone marrow uptake pattern on preoperative 18F-FDG PET/CT in pediatric patients with neuroblastoma. Eur J Nucl Med Mol Imaging 45:306–315

Article  PubMed  Google Scholar 

Li C, Wang S, Li C et al (2022) Improved risk stratification by PET-based intratumor heterogeneity in children with high-risk neuroblastoma. Front Oncol 12:896593

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sung AJ, Weiss BD, Sharp SE, Zhang B, Trout AT (2021) Prognostic significance of pretreatment (18)F-FDG positron emission tomography/computed tomography in pediatric neuroblastoma. Pediatr Radiol 51:1400–1405

Article  PubMed  Google Scholar 

Liu CJ, Lu MY, Liu YL et al (2017) Risk stratification of pediatric patients with neuroblastoma using volumetric parameters of 18F-FDG and 18F-DOPA PET/CT. Clin Nucl Med 42:e142–e148

Article  PubMed  Google Scholar 

Sokol E, Desai AV, Applebaum MA et al (2020) Age, diagnostic category, tumor grade, and Mitosis-Karyorrhexis Index are independently prognostic in neuroblastoma: an INRG project. J Clin Oncol 38:1906–1918

Article  PubMed  PubMed Central  Google Scholar 

Dissaux G, Visvikis D, Da-Ano R et al (2020) Pretreatment (18)F-FDG PET/CT radiomics predict local recurrence in patients treated with stereotactic body radiotherapy for early-stage non-small cell lung cancer: a multicentric study. J Nucl Med 61:814–820

Article  CAS  PubMed  Google Scholar 

Taggart DR, Han MM, Quach A et al (2009) Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma. J Clin Oncol 27:5343–5349

Article  CAS  PubMed  PubMed Central  Google Scholar 

Papathanasiou ND, Gaze MN, Sullivan K et al (2011) 18F-FDG PET/CT and 123I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: diagnostic comparison and survival analysis. J Nucl Med 52:519–525

Article  CAS  PubMed  Google Scholar 

Ko KY, Yen RF, Ko CL et al (2022) Prognostic value of interim 18F-DOPA and 18F-FDG PET/CT findings in stage 3–4 pediatric neuroblastoma. Clin Nucl Med 47:21–25

Article  PubMed  Google Scholar 

Marachelian A, Shimada H, Sano H et al (2012) The significance of serial histopathology in a residual mass for outcome of intermediate risk stage 3 neuroblastoma. Pediatr Blood Cancer 58:675–681

Article  PubMed  Google Scholar 

Iwanaka T, Yamamoto K, Ogawa Y et al (2001) Maturation of mass-screened localized adrenal neuroblastoma. J Pediatr Surg 36:1633–1636

Article  CAS  PubMed  Google Scholar 

Garcia JR, Bassa P, Soler M, Jaramillo A, Ortiz S, Riera E (2019) Benign differentiation of treated neuroblastoma as a cause of false positive by 123I-MIBG SPECT/CT. usefulness of 18F-FDG PET/CT. Rev Esp Med Nucl Imagen Mol (Engl Ed) 38:389–390

CAS  PubMed  Google Scholar 

Sato Y, Kurosawa H, Sakamoto S et al (2015) Usefulness of 18F-fluorodeoxyglucose positron emission tomography for follow-up of 13-cis-retinoic acid treatment for residual neuroblastoma after myeloablative chemotherapy. Medicine (Baltimore) 94:e1290

Article  CAS  PubMed  Google Scholar 

Usmani N, Deyell RJ, Portwine C et al (2021) Residual meta-iodobenzyl guanidine (MIBG) positivity following therapy for metastatic neuroblastoma: patient characteristics, imaging, and outcome. Pediatr Blood Cancer 68:e29289

Article  CAS  PubMed  Google Scholar 

Georgantzi K, Skoldenberg EG, Stridsberg M et al (2018) Chromogranin A and neuron-specific enolase in neuroblastoma: correlation to stage and prognostic factors. Pediatr Hematol Oncol 35:156–165

Article  CAS  PubMed  Google Scholar 

Su Y, Wang L, Wang X et al (2019) Dynamic alterations of plasma cell free DNA in response to chemotherapy in children with neuroblastoma. Cancer Med 8:1558–1566

Article  CAS  PubMed  PubMed Central  Google Scholar 

Simon T, Hero B, Hunneman DH, Berthold F (2003) Tumour markers are poor predictors for relapse or progression in neuroblastoma. Eur J Cancer 39:1899–1903

Article  CAS  PubMed  Google Scholar 

Piccardo A, Morana G, Puntoni M et al (2020) Diagnosis, treatment response, and prognosis: the role of (18)F-DOPA PET/CT in children affected by neuroblastoma in comparison with (123)I-mIBG scan: the first prospective study. J Nucl Med 61:367–374

Article  CAS  PubMed  Google Scholar 

Piccardo A, Lopci E, Conte M et al (2012) Comparison of 18F-dopa PET/CT and 123I-MIBG scintigraphy in stage 3 and 4 neuroblastoma: a pilot study. Eur J Nucl Med Mol Imaging 39:57–71

Article  CAS  PubMed  Google Scholar